Amiodarone Failure-To-Warn Claims Preempted, 3rd Cir. Rules



DOCUMENTS
  • Opinion


CAMDEN, N.J. — The 3rd Circuit U.S. Court of Appeals has upheld dismissal of a multi-plaintiff lawsuit against a manufacturer of generic amiodarone, ruling their claims are preempted because they would require the defendant to issue communications to doctors that go above and beyond those implemented by the name-brand manufacturer.

On July 24, the appellate panel explained that federal law prevents generic manufacturers like Zydus Pharmaceuticals USA Inc. from engaging in communications that surpass the labeling provided by the name-brand manufacturer because they would run the risk of “inaccurately implying a therapeutic difference between the brand and generic drugs and …

FIRM NAMES
  • Morrison Mahoney LLP





UPCOMING CONFERENCES




HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024 - Salt Lake City, UT
The Grand America Hotel

MORE DETAILS